Gilead Stock

YOUR LINK HERE:

http://youtube.com/watch?v=lXYK0rDaMxA

#Valuation: #gilead has a $107 billion market cap and an enterprise value of $127 billion, reflecting its significant role in biotech. The trailing #P/E is high at 105, signaling investor optimism, while the forward P/E of 12 suggests a leaner valuation based on future earnings. A low #PEG of 0.5 hints that the stock might be undervalued relative to its growth, making it attractive for growth-oriented investors. • #Profitability: #Gilead’s profit margin is modest at 3.8%, supported by $28 billion in revenue, positioning it as a major industry player. Its ROA is strong at 11.6%, showing effective asset utilization, though an ROE of 5.3% suggests moderate equity returns. Net income for the year stands at $1.05 billion, and EPS is $0.82, indicating potential for growth but with room for improvement in profitability. • #Balance Sheet and Cash Flow: With $3.8 #billion in #cash, Gilead has liquidity to sustain R D and operations. However, a 128% debt-to-equity ratio shows a heavy reliance on debt, balancing growth with risk. Their levered free cash flow is robust at $6.8 billion, offering strong support for future initiatives. • #Investment Scenarios: • $1,000 Five Years Ago: Investing $1,000 five years ago would now be approximately $1,050, reflecting limited stock growth. • Daily $1 Investment: A daily $1 investment over five years would yield about $1,900, assuming a modest 1% return—steady, if unspectacular growth. • Summary: Gilead Sciences balances modest profitability and substantial cash flow with high debt levels, positioning it as a biotech giant with strong revenue and cash flow but modest recent growth. The low PEG suggests it may be undervalued for growth-oriented investors looking for potential in the biotech space.

#############################

New on site